Literature DB >> 18670086

Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression.

Kang Wang1, Yanling Wang, Lixin Gao, Xinmin Li, Mingming Li, Jianyou Guo.   

Abstract

Intravitreal injection of corticosteroid has been used to treat diabetic macular edema, however, the exact mechanism remains unknown. In the present experiment, four weeks after streptozotocin administration, intravitreal injection of dexamethasone (50 microg/10 microl) was performed. After 2 d injection, we investigated the effect of dexamethasone on leukocyte accumulation, vascular permeability and the expression of vascular endothelial growth factor (VEGF) and intercellular adhesion molecule-1 (ICAM-1) in streptozotocin-diabetic rats. Accumulated leukocytes were counted in vivo by acridine orange leukocyte fluorography, the retinal vascular permeability was measured by the Evans blue assay. The mRNA and protein level of VEGF and ICAM-1 were analyzed with real-time quantitative polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA) respectively. Dexamethasone downregulated VEGF and ICAM-1 expression in diabetic rats which correlated with its effect on leukocytes accumulation and retinal vascular permeability. The present data revealed that dexamethasone may inhibit retinal accumulation and leukostasis accumulation and vascular permeability through its blockage on VEGF and ICAM-1 expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18670086     DOI: 10.1248/bpb.31.1541

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  44 in total

Review 1.  Inflammation in diabetic retinopathy.

Authors:  Johnny Tang; Timothy S Kern
Journal:  Prog Retin Eye Res       Date:  2011-05-25       Impact factor: 21.198

2.  Early and Late Switch from Ranibizumab to an Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema in the Event of a Poor Anatomical Response.

Authors:  Gokhan Demir; Abdullah Ozkaya; Elmas Yuksel; Gurkan Erdogan; Ugur Tunc; Mevlut Celal Ocal; Yasin Sakır Goker
Journal:  Clin Drug Investig       Date:  2020-02       Impact factor: 2.859

3.  Treatment of inflammatory macular edema with humanized anti-CD11a antibody therapy.

Authors:  Lisa J Faia; H Nida Sen; Zhuqing Li; Steven Yeh; Keith J Wroblewski; Robert B Nussenblatt
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-01       Impact factor: 4.799

4.  A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.

Authors:  David G Callanan; Anat Loewenstein; Sunil S Patel; Pascale Massin; Borja Corcóstegui; Xiao-Yan Li; Jenny Jiao; Yehia Hashad; Scott M Whitcup
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-09-08       Impact factor: 3.117

5.  A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5.

Authors:  Michael S Ip; Ingrid U Scott; Paul C VanVeldhuisen; Neal L Oden; Barbara A Blodi; Marian Fisher; Lawrence J Singerman; Michael Tolentino; Clement K Chan; Victor H Gonzalez
Journal:  Arch Ophthalmol       Date:  2009-09

Review 6.  Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema.

Authors:  Marco Dutra Medeiros; Micol Alkabes; Paolo Nucci
Journal:  Eur Endocrinol       Date:  2014-08-28

7.  Inhibition of high glucose-induced VEGF and ICAM-1 expression in human retinal pigment epithelium cells by targeting ILK with small interference RNA.

Authors:  Wei Wang; Makoto Matsukura; Isao Fujii; Kaori Ito; Ji En Zhao; Makoto Shinohara; Ye Qing Wang; Xiao Mei Zhang
Journal:  Mol Biol Rep       Date:  2011-05-07       Impact factor: 2.316

8.  Increase of aqueous inflammatory factors in macular edema with branch retinal vein occlusion: a case control study.

Authors:  Hidetaka Noma; Hideharu Funatsu; Tatsuya Mimura; Katsunori Shimada
Journal:  J Inflamm (Lond)       Date:  2010-08-26       Impact factor: 4.981

Review 9.  Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema.

Authors:  Hemal Mehta; Mark Gillies; Samantha Fraser-Bell
Journal:  Ther Adv Chronic Dis       Date:  2015-09       Impact factor: 5.091

10.  A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6.

Authors:  Ingrid U Scott; Michael S Ip; Paul C VanVeldhuisen; Neal L Oden; Barbara A Blodi; Marian Fisher; Clement K Chan; Victor H Gonzalez; Lawrence J Singerman; Michael Tolentino
Journal:  Arch Ophthalmol       Date:  2009-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.